Kobayashi Eriko, Satoh Nobunori
Department of Drug Information and Communication, Graduate School of Pharmaceutical Sciences, Chiba University, 1-8-1 Inohana, Chuo-ku, Chiba, Chiba, 260-8675, Japan.
Cell Tissue Bank. 2009 Nov;10(4):281-91. doi: 10.1007/s10561-009-9145-0. Epub 2009 Jul 23.
To assess the attitudes of the Japanese general public towards pharmacogenomics research and a DNA bank for identifying genomic markers associated with ADRs and their willingness to donate DNA samples, we conducted a national survey for 1,103 Japanese adults from the general public, not a patient population. The response rate was 36.8%. The majority of the respondents showed a positive attitude towards pharmacogenomics research (81.0%) and a DNA bank (70.4%). Considering fictitious clinical situations such as taking medications and experiencing ADRs, the willingness to donate DNA samples when experiencing ADRs (61.7%) was higher than when taking medications (45.3%). Older generations were significantly associated with a decreased willingness to donate (OR = 0.45, CI 0.28-0.72 in 50s. OR = 0.49, CI: 0.31-0.77 in 60s). Positive attitudes towards pharmacogenomics research, a DNA bank, blood/bone marrow/organ donation were significantly associated with an increased willingness. However, the respondents had the following concerns regarding a DNA bank: the confidentiality of their personal information, the manner by which research results were utilized and simply the use of their own DNA for research. In order to attain public understanding to overcome these concerns, a process of public awareness should be put into place to emphasize the beneficial aspects of identifying genomic markers associated with ADRs and to address these concerns raised in our study. Further study is needed to assess the willingness of actual patients taking medications in real situations, since the respondents in our study were from the general public, not a patient population, and their willingness was assessed on the condition of assuming that they were patients taking medications.
为了评估日本普通公众对药物基因组学研究以及用于识别与药物不良反应相关基因组标记的DNA库的态度,以及他们捐赠DNA样本的意愿,我们对1103名来自普通公众而非患者群体的日本成年人进行了一项全国性调查。回复率为36.8%。大多数受访者对药物基因组学研究(81.0%)和DNA库(70.4%)持积极态度。考虑到虚构的临床情况,如服药和经历药物不良反应,经历药物不良反应时捐赠DNA样本的意愿(61.7%)高于服药时(45.3%)。老一辈捐赠意愿显著降低(50多岁时OR = 0.45,CI 0.28 - 0.72;60多岁时OR = 0.49,CI:0.31 - 0.77)。对药物基因组学研究、DNA库、血液/骨髓/器官捐赠持积极态度与捐赠意愿增加显著相关。然而,受访者对DNA库有以下担忧:个人信息的保密性、研究结果的使用方式以及仅仅是自己的DNA被用于研究。为了获得公众理解以克服这些担忧,应该开展一个公众意识提升过程,强调识别与药物不良反应相关基因组标记的有益方面,并解决我们研究中提出的这些担忧。由于我们研究的受访者来自普通公众而非患者群体,且他们的意愿是在假设自己是服药患者的情况下评估的,因此需要进一步研究来评估实际服药患者在真实情况下的捐赠意愿。